Pharma Reaserch Prod Co Ltd (214450) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Pharma Reaserch Prod Co Ltd KRW 492,298, price KRW 322,500, upside +52.7%, quality 78 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Pharma Reaserch Prod Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 54,109 KRW – 708,934 KRW · fair‑value band 287,400 KRW – 1,129,180 KRW · the 322,500 KRW price screens below the 492,298 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Pharma Reaserch Prod Co in your weekly email
Every Wednesday you see whether Pharma Reaserch Prod Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea.
Show more
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.
Stock analysis
Pharma Reaserch Prod Co Ltd (214450) currently trades at 322,500 KRW, while our model-based Fair Value estimate is 492,298 KRW, implying the stock looks roughly 34.5% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 731,541 KRW per share, and 16 of the 26 models we run sit above the 322,500 KRW price.
Bear case: the Economic Profit group reads lowest at 177,338 KRW, and 10 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: 287,400 KRW (bear) to 1,129,180 KRW (bull), the price of 322,500 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 78/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Pharma Reaserch Prod Co Ltd reported revenue of 536B KRW in FY2025 versus 154B KRW in FY2021, a compound +36.6%/yr. Reported net income was 165B KRW in FY2025, compounding +37.1%/yr from FY2021.
Key figures
Market cap 3.4T KRW (≈ $2.3B) · P/S ratio 6.18 · Dividend yield 1.1% · Net margin 30.8% · Return on equity 27.3% · Return on assets (EBIT) 15.3% · Operating margin 39.4% · Revenue (TTM) 565B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 53%, 214450 screens cheaper than that median.
Fair Value models
Bear 287,400 KRWFair Value 492,298 KRWBull 1,129,180 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+53.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.6%
Start year 2020 (pandemic). Over 10 years: +30.5% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+36.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+35.7%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.36% vs 27%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.30% → 40%
2025 sits 112% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+18.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +2.5% a year for the price and +16.2% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (63 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare Pharma Reaserch Prod Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 9/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score78 · Top 25%
Fair Value upside+53% · Top 25%
Profitability
Return on equity (TTM)27% · Top 25%
Return on assets14% · Top 25%
Net margin (TTM)31% · Top 25%
Operating margin (TTM)39% · Top 25%
Growth and dividend
Revenue growth25% · Top 25%
Dividend yield (TTM)1.1% · Below median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pharma Reaserch Prod Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/214450
Frequently asked questions
Is Pharma Reaserch Prod Co Ltd (214450) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 492,298 KRW versus a price of 322,500 KRW, about +53% upside (undervalued).
What is the fair value of 214450?
Our model-based fair value for Pharma Reaserch Prod Co Ltd is 492,298 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 322,500 KRW.
What is the quality score of 214450?
Pharma Reaserch Prod Co Ltd has a Quality Score of 78/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharma Reaserch Prod Co Ltd (214450)?
Our model-based price target is the fair value of 492,298 KRW (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 287,400 KRW, optimistic scenario 1,129,180 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharma Reaserch Prod Co Ltd stock forecast for 2026?
Our models put fair value at 492,298 KRW, about +53% upside versus a price of 322,500 KRW (undervalued). Cautious scenario 287,400 KRW, optimistic scenario 1,129,180 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Pharma Reaserch Prod Co Ltd (214450)?
Pharma Reaserch Prod Co Ltd reported trailing-twelve-month revenue of about 565B KRW (latest available figure, as of Sep 24, 2026).
Does Pharma Reaserch Prod Co Ltd pay a dividend?
Pharma Reaserch Prod Co Ltd currently shows a dividend yield of about 1.15% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Pharma Reaserch Prod Co Ltd (214450)?
For today's price to be fair in a discounted-cash-flow model, Pharma Reaserch Prod Co Ltd would have to grow free cash flow by +4.7 % per year for five years (discount rate 8.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +37.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 214450 use?
Our models discount Pharma Reaserch Prod Co Ltd at 8.0 %: a base by market capitalisation (mega), damped by beta 0.44, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pharma Reaserch Prod Co Ltd that is +4.7 % per year a year over ten years, using the same discount rate (8.0 %) and the same formula as our fair value.
How much growth has Pharma Reaserch Prod Co Ltd (214450) delivered so far?
Over the past 5 years revenue at Pharma Reaserch Prod Co Ltd grew +37.6 % a year. The price currently implies +4.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pharma Reaserch Prod Co Ltd (214450) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Pharma Reaserch Prod Co Ltd (+4.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pharma Reaserch Prod Co Ltd (214450)?
The free-cash-flow yield on the price is 4.40 %: that much free cash flow Pharma Reaserch Prod Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pharma Reaserch Prod Co Ltd (214450)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharma Reaserch Prod Co Ltd it is 492,298 KRW per share (as of Sep 24, 2026), against a price of 322,500 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Pharma Reaserch Prod Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 214450 trades below its calculated fair value: price 322,500 KRW, fair value 492,298 KRW, a gap of about +53% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 214450?
No. The price is what the market pays today (322,500 KRW); the fair value is what the company's own numbers justify (492,298 KRW). For Pharma Reaserch Prod Co Ltd the two are 169,798 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharma Reaserch Prod Co Ltd worth?
The market values Pharma Reaserch Prod Co Ltd at about 3.4T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 322,500 KRW; our models calculate a fair value of 492,298 KRW per share.
What do the bullish and bearish scenarios say about 214450?
Our models span a range for Pharma Reaserch Prod Co Ltd: cautious scenario 287,400 KRW, base 492,298 KRW, optimistic 1,129,180 KRW per share (as of Sep 24, 2026, price 322,500 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharma Reaserch Prod Co Ltd (214450)?
Balance-sheet figures for Pharma Reaserch Prod Co Ltd (as of Sep 24, 2026): return on equity 27.3%, debt of 0.00 per unit of equity. They feed the Quality Score of 78/100, which measures business quality independently of the share price.
How far is 214450 from its 52-week high?
Pharma Reaserch Prod Co Ltd trades at 322,500 KRW, about 46% below its 52-week high of 600,250 KRW and 25% above the low of 259,000 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 492,298 KRW is for.
Which stocks are comparable to Pharma Reaserch Prod Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharma Reaserch Prod Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 322,500 KRW, calculated fair value 492,298 KRW (+53%), Quality Score 78/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 214450 calculated?
We run Pharma Reaserch Prod Co Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 492,298 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Pharma Reaserch Prod Co Ltd currently trades 53 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharma Reaserch Prod Co Ltd (214450)?
The closing price on Sep 23, 2026 was 322,500 KRW. Our model-based fair value is 492,298 KRW, about +53% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharma Reaserch Prod Co Ltd right now?
The rarer combination: high quality (78/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide (287,400 KRW to 1,129,180 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Pharma Reaserch Prod Co Ltd
How large is the market capitalisation of Pharma Reaserch Prod Co Ltd (214450)?
The market capitalisation of Pharma Reaserch Prod Co Ltd is 3.4T KRW (≈ $2.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharma Reaserch Prod Co Ltd (214450)?
The price-to-sales ratio of Pharma Reaserch Prod Co Ltd is 6.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Pharma Reaserch Prod Co Ltd (214450)?
The dividend yield of Pharma Reaserch Prod Co Ltd is 1.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharma Reaserch Prod Co Ltd (214450)?
The net margin of Pharma Reaserch Prod Co Ltd is 30.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharma Reaserch Prod Co Ltd (214450)?
The return on equity (ROE) of Pharma Reaserch Prod Co Ltd is 27.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharma Reaserch Prod Co Ltd (214450)?
On an EBIT basis the return on assets of Pharma Reaserch Prod Co Ltd is 15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharma Reaserch Prod Co Ltd (214450)?
The operating margin of Pharma Reaserch Prod Co Ltd is 39.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharma Reaserch Prod Co Ltd (214450)?
Revenue at Pharma Reaserch Prod Co Ltd is growing +25.0% versus a year earlier (3y avg +40.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pharma Reaserch Prod Co Ltd (214450)?
Earnings per share at Pharma Reaserch Prod Co Ltd are growing +29.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Pharma Reaserch Prod Co Ltd (214450) carry?
The net debt of Pharma Reaserch Prod Co Ltd is 19.8B KRW (fiscal year 2021, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pharma Reaserch Prod Co Ltd in the live analysis
One click puts Pharma Reaserch Prod Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
